The Economic Impact of Neuropsychiatric Symptoms in Alzheimer’s Disease: Can Drugs Ease the Burden?

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.23, Iss.3, 2005-01, pp. : 227-242

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Does Pharmacological Treatment of Neuropsychiatric Symptoms in Alzheimer's Disease Relieve Caregiver Burden?

By Levy Karen Lanctôt Krista L. Farber Shale B. Li Abby Herrmann Nathan

Drugs & Aging, Vol. 29, Iss. 3, 2012-03 ,pp. : 167-179

Adis International

Access to resources Recommend Favorite

Efficacy of praziquantel correlated to disease burden?

Inpharma, Vol. 1, Iss. 1229, 2000-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

What are the Treatment Options for Patients with Severe Alzheimers Disease?

By Voisin T.

CNS Drugs, Vol. 18, Iss. 9, 2004-01 ,pp. : 575-583

Adis International

Access to resources Recommend Favorite

Impact of Estrogen Therapy on Alzheimer's Disease: A Fork in the Road?

By Brinton R.D.

CNS Drugs, Vol. 18, Iss. 7, 2004-01 ,pp. : 405-422

Adis International

Access to resources Recommend Favorite

Atypical Antipsychotics for Neuropsychiatric Symptoms of Dementia: Malignant or Maligned?

By Herrmann Nathan Lanctôt Krista L.

Drug Safety, Vol. 29, Iss. 10, 2006-01 ,pp. : 833-843

Adis International

Access to resources Recommend Favorite